Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer.

PURPOSE The assessment of prognosis and decisions on treatment for patients with non-small-cell lung cancer (NSCLC) are determined on the basis of disease stage and performance status. NSCLC frequently manifests loss of heterozygosity (LOH) at chromosome segment 11p15.5. Whether LOH at 11p15.5 is an independent prognostic variable has yet to be determined. PATIENTS AND METHODS We developed five novel markers, which can be assessed by polymerase chain reaction and restriction enzyme digestion. LOH at 11p15.5 was assessed in 193 patients who underwent surgical resection for pathologic stage I and II of the disease. RESULTS LOH at 11p15.5 was associated with poor survival (P =.021). Multivariate logistic regression analysis showed that after disease stage, performance status, weight loss, sex, age at diagnosis, and smoking history were controlled for, patients with LOH were two times more likely to die than those without LOH (relative risk [RR] = 2.01, P =.021). Cox regression analysis with disease stage and LOH revealed that the survival of patients with stage I disease and LOH was similar to the survival of patients with stage II disease, and it was significantly worse than the survival of stage I patients without LOH (RR = 2.38, P =.038). CONCLUSION LOH in a 310-kb region on chromosome segment 11p15.5 that includes the gene for the regulatory subunit of the enzyme ribonucleotide reductase is highly predictive of poor survival from NSCLC. The future utility of analysis of the allelic status of this region may involve treatment decisions, such as the use of neoadjuvant and adjuvant chemotherapy for patients with stage I disease.

[1]  G. Bepler,et al.  Transcript map and complete genomic sequence for the 310 kb region of minimal allele loss on chromosome segment 11p15.5 in non-small-cell lung cancer , 2001, Oncogene.

[2]  G. Bepler,et al.  MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Jett,et al.  Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Yuan,et al.  Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Dupont,et al.  Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Bepler,et al.  Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1) , 1999, Mammalian Genome.

[7]  E. Brambilla,et al.  Alterations of expression of Rb, p16INK4A and cyclin D1 in non‐small cell lung carcinoma and their clinical significance , 1999, The Journal of pathology.

[8]  N. Weidner,et al.  Prognostic Markers in Resected Non–Small-Cell Lung Cancer: An Patients with 5 Year Follow-Up , 1999 .

[9]  E. Brambilla,et al.  Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  J. Minna,et al.  Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  G. Bepler,et al.  A 1.4-Mb high-resolution physical map and contig of chromosome segment 11p15.5 and genes in the LOH11A metastasis suppressor region. , 1999, Genomics.

[12]  D. Sugarbaker,et al.  Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study. , 1998, Lung cancer.

[13]  M. Volm,et al.  Prognostic value of p16INK4A expression in lung adenocarcinoma. , 1998, Anticancer research.

[14]  M. Jasin,et al.  Homology-directed repair is a major double-strand break repair pathway in mammalian cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Niewoehner,et al.  Do molecular markers predict survival in non-small-cell lung cancer? , 1998, American journal of respiratory and critical care medicine.

[16]  J. Wright,et al.  The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  G. Bepler,et al.  Growth inhibition of a human lung adenocarcinoma cell line by genetic complementation with chromosome 11. , 1997, Anticancer research.

[18]  R. Rosell,et al.  Microsatellite alterations at 5q21, 11p13, and 11p15.5 do not predict survival in non-small cell lung cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  R. Rosell,et al.  Reduced survival in patients with stage‐I non‐small‐cell lung cancer associated with DNA‐replication errors , 1997, International journal of cancer.

[20]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[21]  G. Bepler,et al.  Smoking, gender, and survival association with allele loss for the LOH11B lung cancer region on chromosome 11. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  A. Gazdar,et al.  Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  I. Newsham,et al.  High-density marker analysis of 11p15.5 in non-small cell lung carcinomas reveals allelic deletion of one shared and one distinct region when compared to breast carcinomas. , 1996, Cancer research.

[24]  W. Richards,et al.  Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. , 1996, The Annals of thoracic surgery.

[25]  K. Pantel,et al.  Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases , 1996, The Lancet.

[26]  P. Zimmerman,et al.  Tumor progression and loss of heterozygosity at 5q and 18q in non-small cell lung cancer. , 1995, Cancer research.

[27]  P. Rouet,et al.  Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. , 1994, Molecular and cellular biology.

[28]  V. Rusch,et al.  p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. , 1994, Chest.

[29]  Z. F. Liu,et al.  Allelic loss of chromosome 18q and prognosis in colorectal cancer. , 1994, The New England journal of medicine.

[30]  P. Zimmerman,et al.  Correlation of loss of heterozygosity at 11 p with tumour progression and survival in non‐small cell lung cancer , 1994, Genes, chromosomes & cancer.

[31]  G. Bepler,et al.  Three tumor-suppressor regions on chromosome 11p identified by high-resolution deletion mapping in human non-small-cell lung cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Stahel,et al.  Allelic loss on the short arm of chromosome 11 in non‐small‐cell lung cancer , 1991, International journal of cancer.

[33]  S. Rodenhuis,et al.  Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. , 1991, Journal of the National Cancer Institute.

[34]  A. Sahin,et al.  Expression of blood-group antigen A--a favorable prognostic factor in non-small-cell lung cancer. , 1991, The New England journal of medicine.

[35]  D. Weiner,et al.  p185neu expression in human lung adenocarcinomas predicts shortened survival. , 1990, Cancer research.

[36]  T R Fleming,et al.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. , 1990, The New England journal of medicine.

[37]  J. Willey,et al.  Differential DNA sequence deletions from chromosomes 3, 11, 13, and 17 in squamous-cell carcinoma, large-cell carcinoma, and adenocarcinoma of the human lung. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Noguchi,et al.  Loss of genes on the short arm of chromosome 11 in human lung carcinomas. , 1987, Japanese journal of cancer research : Gann.

[39]  T. P. Dryja,et al.  Expression of recessive alleles by chromosomal mechanisms in retinoblastoma , 1983, Nature.

[40]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[41]  K. Sugimachi,et al.  K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. , 1997, British Journal of Cancer.

[42]  G. Giovino,et al.  Epidemiology of tobacco use and dependence. , 1995, Epidemiologic reviews.

[43]  M. Oshimura,et al.  Suppression of tumorigenicity of A549 lung adenocarcinoma cells by human chromosomes 3 and 11 introduced via microcell‐mediated chromosome transfer , 1993, Molecular carcinogenesis.

[44]  S. Steinberg,et al.  p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. , 1992, Oncogene.